Cytokeratins - Clinical utility in breast cancer

被引：0

作者：

Barak, V ^{[1
]}

Nisman, B ^{[1
]}

Hubert, A ^{[1
]}

Lyass, O ^{[1
]}

Peretz, T ^{[1
]}

机构：

[1] Hadassah Univ Hosp, Dept Oncol, Immunol Lab Tumor Diagnosis, IL-12000 Jerusalem, Israel

来源：

JOURNAL OF CLINICAL LIGAND ASSAY | 2002年 / 25卷 / 01期

关键词：

cytokeratins; TPS; breast cancer; prognosis; monitoring;

D O I：

暂无

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Cytokeratins belong to the intermediate filament protein family which is a component of the cytoskeleton of epithelial cells. The most abundant cytokeratins present in epithelial tumors are cytokeratins 8,18, and 19. TPA, TPS, and CYFRA 21-1, based on fragments of these cytokeratins, are the three cytokeratin markers in clinical use today. They are mainly used for treatment monitoring in cancer patients, but also for diagnosis (in lung carcinoma) and for prognosis in several types of cancers, especially in breast cancer.

引用

页码：40 / 42

页数：3

共 24 条

[1] Barak V., 1998, Anticancer Research, V18, P4982
[2] Barak V, 1997, J TUMOR MARKER ONCOL, V12, P17
[3] Barak V., 1998, Tumor Biology, V19, P59
[4] BARAK V, 1994, J TUMOR MARKER ONCOL, V9, P89
[5] BARAK V, 1995, J TUMOR MARKER ONCOL, V10, P51
[6] Bjorklund B, 1996, TUMORDIAGN THER, V17, P67
[7] BJORKLUND B, 1987, HUMAN TUMOR MARKERS, P169
[8] BJORKLUND B, 1993, UPDATING TUMOR MARKE, P651
[9] BUCCHERI GF, 1989, CHEST, V93, P565
[10] Ebert W., 1998, Anticancer Research, V18, P4983

← 1 2 3 →